Introduction
In recent years, therapeutic considerations in metastatic colorectal cancer (mCRC) have been influenced considerably by the advent of monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), an oncogene frequently expressed in various solid tumors, triggering incessant proliferation through a number of interrelated pathways [1] [2] [3] [4] . Cetuximab and panitumumab, used either alone or in combination with chemotherapeutic agents, have been shown to improve the outcome of mCRC patients [5] [6] [7] [8] [9] . Soon after these agents were introduced into clinical practice, retrospective studies reported a significant correlation between Kirsten rat sarcoma viral oncogene homolog (KRAS) mutational status and therapeutic efficacy, proposing that alterations of this gene, which encodes for a membrane-associated guanosine triphosphatase that influences downstream signaling, might account for inherent resistance to EGFR-targeting mAbs [10] [11] [12] [13] [14] [15] [16] .
Mutations of the KRAS gene most frequently occur in codons 12 and 13 of exon 2: depending on the specific amino acid exchange involved, they are termed G12A, G12C, G12D, G13D, G12R, G12S, and G12V [17] . These mutations activate several intracellular pathways, causing resistance against EGFR-targeting mAbs [18, 19] . As a consequence, treatment with cetuximab and panitumumab has been restricted to patients bearing KRAS wild-type tumors, which account for ∼ 60% of all mCRCs [17, 20] . Interestingly, as described by De Roock et al. [21] , mutations of the KRAS gene are not entirely homogeneous. Some KRAS mutants (G13D in particular) may still respond to treatment with cetuximab/panitumumab, suggesting a varying degree of resistance in KRAS variants [22] . These findings indicate the need for further discrimination of KRAS subtypes, with a particular focus on the identification of those KRAS mutants showing sensitivity to promising drugs currently withheld from respective patients.
Similar to mAbs, small molecule tyrosine kinase inhibitors (TKIs) such as afatinib or gefitinib were also developed to interfere with the above-mentioned structures. Gefitinib acts as a reversible inhibitor of the EGFR tyrosine kinase domain and has proven to be effective in a fraction of patients with non-small-cell lung carcinoma [23] [24] [25] [26] . By contrast, afatinib irreversibly interferes with an entire set of proteins belonging to the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases, including EGFR and HER-2 [27] . Afatinib is being evaluated in various clinical trials concerning non-small-cell lung carcinoma, metastatic breast cancer, and advanced pancreatic cancer [28] [29] [30] . Homodimerization or heterodimerization among members of the HER family is an essential and early step in signal transduction following EGFR ligand binding [1, 31, 32] . Although HER-2 has been shown to be the preferred binding partner for other HER receptors, HER-3, although capable of binding ligands, appears to be lacking intrinsic tyrosine kinase activity, thus requiring further downstream signaling to be induced by its respective partner [33, 34] .
The means by which mutations in the KRAS gene render tumor cell proliferation (at least partly) independent of EGFR stimulation might affect the efficacy of TKIs in a similar manner as observed with mAbs: direct activation of mitogen/extracellular signal-regulated kinase (MEK)/ extracellular-signal-regulated kinase (ERK) and phosphatidylinositide 3-kinase (PI3K)/protein kinase B (AKT) pathways by KRAS is possibly causing TKIs to become ineffectual in KRAS mutant tumors [35] [36] [37] [38] [39] [40] . At this point, however, it is not entirely conclusive to what extent other members of the HER family are involved in this matter and what influence different mutations within the KRAS gene truly have on the expression of different EGFRrelated receptors and their susceptibility to treatment. This in-vitro study aims to characterize the varying effect of afatinib/gefitinib on isogenic colorectal cancer cell lines harboring the seven most frequent mutations in the KRAS gene and to decipher the respective contribution of EGFR, HER-2, HER-3, ERK, and AKT to the degree of sensitivity observed in those cells.
Materials and methods

Cell lines
All experiments were conducted using the human colon adenocarcinoma cell line SW48 (obtained from Horizon Discovery, Cambridge, UK). Apart from the mother cell line expressing wild-type KRAS, seven other cell lines harboring the most frequent mutations located in codons 12 and 13 of exon 2 of the KRAS gene (G12A/G12C/G12D/G13D/G12R/ G12S/G12V) were available for the purpose of this investigation. Horizon Discovery engineered these KRAS mutant cell lines using a recombinant adeno-associated viral vector [41] [42] [43] .
KRAS-testing/KRAS-quantification
To confirm the KRAS mutation status of all acquired cell lines, detailed analysis was subsequently carried out by a German laboratory licensed for KRAS-testing (Department of Pathology, University of Munich, Munich, Germany). Specific detection of KRAS mutations was performed using Qiagen PyroMark Gold (Qiagen, Venlo, Netherlands) reagents in combination with a Q24 pyrosequencing device [44] . All the cell lines examined were shown to express comparable amounts of KRAS protein.
Cell culture
Cells were maintained in McCoy's 5A medium (Life Technologies, Carlsbad, California, USA) supplemented with 100 ml/l fetal bovine serum (Biochrom, Berlin, Germany), 100 U/ml penicillin, and 100 μg/ml streptomycin (PAN Biotech, Aidenbach, Germany). They were incubated at 37°C in an atmosphere of 50 ml/l CO 2 and 950 ml/l air. Medium was changed every 3 days and cells were subcultured regularly once confluency of about 70% was reached.
Drugs
Afatinib was kindly provided by Boehringer Ingelheim (Ingelheim, Germany). Gefitinib was purchased from LC Laboratories (Woburn, Massachusetts, USA).
Colorimetric cell viability assay
Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Gaithersburg, Maryland, USA) was used for colorimetric assessment of cell viability. We began by seeding 3000 cells/well in 96-well tissue culture plates. After 24 h of incubation at 37°C, adherent cells were exposed to increasing concentrations of afatinib/gefitinib. Following another 48 h of incubation, CCK-8 solution was added to each well according to the manufacturer's recommendations. Cell viability was evaluated using an ELISA plate reader, measuring optical density at a wavelength of 450 nm. The mean IC 50 values were calculated after conducting three separate and independent experiments for each cell line and therapeutic setup.
Quantification of proliferating and apoptotic cells using flow cytometry
Nonconfluent cells were seeded at 75 000 cells/well in sixwell tissue culture plates and incubated at 37°C. Afatinib/ gefitinib was added after 24 h using the IC 50 value determined previously for each respective drug in SW48 KRAS wild-type cells. After an additional 48 h of incubation, cells were collected and suspended in Nicoletti buffer (1 mg/ml sodium citrate at pH 7.4, 1 mg/ml Triton X-100, and 50 μg/ml propidium iodide). Nuclear DNA content was subsequently measured using a fluorescenceactivated cell sorter (Becton Dickinson, Heidelberg, Germany). Mean values were calculated from the results of three separate and independent experiments.
Western blot analysis of protein expression
Cells were treated with afatinib/gefitinib once confluency of about 70% was reached. As described above, we used IC 50 values evaluated previously for KRAS wild-type cells. After a period of 48 h, cells were washed with ice-cold PBS and resuspended in ice-cold complete lysis-M buffer (Roche, Mannheim, Germany) supplemented with 5 mmol/l sodium vanadate (Sigma-Aldrich, St. Louis, Missouri, USA), yielding a final concentration of 10 7 -10 8 cells/ml. Equal amounts of protein were resolved by SDS-PAGE and blotted to polyvinylidene difluoride membranes (Merck Millipore, Billerica, Massachusetts, USA). Proteins of interest were detected using quantum dots (Invitrogen, Karlsruhe, Germany) as well as specific antibodies against phosphorylated/total EGFR, HER-2, HER-3, ERK, and AKT (Cell Signaling Technology, Danvers, Massachusetts, USA). β-Actin served as a loading control. All antibodies were used according to the manufacturer's instructions.
Statistical analysis
Data were summarized using appropriate measures of location and spread. A two-way analysis of variance with a factor indicating the type of treatment (afatinib and gefitinib), a factor indicating the cell lines (WT, G12A, G12C, G12D, G13D, G12R, G12S, and G12V), and with the interaction of both factors was carried out. To compare pairwise mean differences, the P-values from Tukey's honest significant difference method was used to control the family-wise type I error rate. All tests were two-sided and adjusted P-values less than 0.05 were considered statistically significant. The statistical software R (version 2.13.1; R Foundation for Statistical Computing, Vienna, Austria) was used for all calculations.
Results
Colorimetric cell viability assay
Compared with KRAS wild-type cells, G13D and G12A mutant cells were more sensitive to gefitinib; all other mutant subtypes were less susceptible to this drug. Except for one case (G12A), these differences were statistically significant (P < 0.01). A similar pattern was observed following treatment with afatinib: G13D and G12A mutant cells seemed to be more sensitive compared with KRAS wild-type cells, whereas the other mutant subtypes appeared to be less responsive to afatinib than KRAS wild-type cells. However, the differences found for afatinib were not statistically significant. Overall, a 50% decrease in cell viability was achieved at concentrations of 3.0-7.7 μmol/l for afatinib and 5.4-19.5 μmol/l for gefitinib ( Fig. 1 ).
Quantification of proliferating and apoptotic cells
Cell cycle analysis was carried out in KRAS wild-type/ mutant cells following 48 h of treatment, comparing the amount of apoptotic/proliferating cells in treated/ untreated samples ( Fig. 2a-c) . The influence of gefitinib on apoptosis appeared to be greater in KRAS wild-type cells than in KRAS mutant cell lines. Although treatment resulted in higher rates of apoptotic cells in some mutant variants, compared with the average fraction of apoptotic cells in treated KRAS mutant cells, treatment resulted in 1.7 times as many apoptotic cells in KRAS wild-type cells. Similar to gefitinib, afatinib had a larger impact on apoptosis in KRAS wild-type cells than in KRAS mutant cells. In G12C/G13D/G12S mutant cells treated with afatinib, the fraction of apoptotic cells was 4.8-6.9 times as high as in untreated samples. By contrast, afatinib (like gefitinib) did not increase the number of apoptotic cells in G12A/G12V mutant cells. Differences between KRAS variants in terms of apoptosis did not reach significance. Generally, afatinib seemed to produce a considerably higher amount of apoptotic cells than gefitinib across all cell lines (on average, the number of apoptotic cells after treatment with afatinib was 2.6 times as high as the corresponding value following treatment with gefitinib; P < 0.01).
In most cell lines, cell proliferation decreased following treatment with gefitinib. The number of proliferating cells was particularly reduced in G12C/G12D/G13D mutant cells, being merely 0.6-0.7 times as high as in untreated samples. Cell proliferation was also inhibited by afatinib, with G12C/G12D/G13D mutant cells also being most affected in this respect (0.2-0.4 times as many proliferating cells as in untreated samples). Consistent with its effect on apoptosis, afatinib appeared to have a stronger impact on proliferation than gefitinib. However, differences in cell proliferation were not found to be statistically significant.
Evaluation of EGFR/pEGFR, HER-2/pHER-2, and HER-3/pHER-3 protein levels
Owing to the fact that afatinib/gefitinib exert effects by inhibiting different members of the HER family, we aimed to evaluate protein levels of total EGFR, HER-2, and HER-3 before/after treatment ( Fig. 3a-d) . The expression of these receptor proteins appeared to be rather similar among treated/untreated KRAS wild-type/ mutant cell lines. On examining two different sites of 
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WT G13D G12A G12R G12V G12S G12D G12C IC 50 (μmol/l) * * * phosphorylation (Tyr845/Tyr992), we found that levels of phosphorylated EGFR were affected by treatment with afatinib/gefitinib. In cells treated with gefitinib, Tyr992 phosphorylation was reduced on average by 49% compared with untreated samples; Tyr845 phosphorylation was reduced by 2%. The decrease in pEGFR was relatively pronounced in G13D/G12S/G12V mutant cells and only moderate in G12A/G12C mutant subtypes. On average, afatinib reduced Tyr992 phosphorylation by 74% and Tyr845 phosphorylation by 56%. Again, G13D/G12S/G12V mutant cells were more responsive than G12A/G12C mutant subtypes in this respect. Across all cell lines, afatinib was shown to suppress EGFR activation more effectively than gefitinib (P < 0.001). Upon treatment with gefitinib, the expression of pHER-2 remained close to pretherapeutic levels in G12C/G12D mutant cells (decreasing by 7%) and in KRAS wild-type/G13D mutant cells (increasing by 2-7%). G12A/G12R/G12V mutant subtypes seemed to be affected to a greater extent, with levels of pHER-2 decreasing by 30-48%. By contrast, treatment with afatinib resulted in a decrease in pHER-2 levels in all except two cell lines (G12C/G13D). KRAS wild-type as well as G12A/G12V mutant cells were most susceptible to the inhibition of HER-2 phosphorylation by afatinib (pHER-2 levels were reduced by 51-59%). Overall, afatinib could suppress HER-2 activation to a greater extent than gefitinib: on average, the levels of pHER-2 decreased by 34 and 16%, respectively (P < 0.01). The levels of phosphorylated HER-3 generally did not seem to be affected much by either drug.
Evaluation of ERK/pERK and AKT/pAKT protein levels
We further investigated the expression of several proteins mediating downstream signaling along MEK/ERK and PI3K/AKT pathways, comparing the effect of afatinib/ gefitinib on KRAS wild-type/mutant cells (Fig. 3a, e, f) . Once again, we found similar amounts of total ERK/AKT across all cell lines. Although the levels of pERK were also mostly similar in untreated KRAS mutant/wild-type cells, treatment with gefitinib was shown to elicit strong inhibitory effects on this pathway, leading to a 41-51% decrease of pERK in KRAS wild-type as well as G12S/G12V mutant cells; a more thorough inhibition was observed in G12C/G13D/G12R mutant subtypes (88-96%). In contrast, afatinib reduced levels of pERK the least in KRAS wild-type cells (84%) and the most in G13D/G12V mutant cells (>99%). Our results indicate afatinib to generally have a stronger inhibitory influence on pERK than gefitinib (on average, the levels of pERK were reduced by 94 and 
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Evaluation of protein levels without (− ) and with treatment with afatinib (A) or gefitinib (G). Western blot (a). Relative phosphorylation of the target proteins was quantified by densitometry (b-f). Mutant subtypes (MT) were compared with Kirsten rat sarcoma viral oncogene homolog (KRAS) wildtype cells (WT) of the same treatment group. AKT, protein kinase B; EGFR, epidermal growth factor receptor; ERK, extracellular-signal-regulated kinase; HER-2, human epidermal growth factor receptor 2.
69%, respectively; P < 0.001). Levels of phosphorylated AKT were largely similar among untreated KRAS wildtype/mutant cell lines. Treatment with gefitinib resulted in a slight decrease in pAKT levels in G12S/G12V (18-22%) and a more pronounced reduction in G12A/G12D/G12R mutant cells (85-87%). Afatinib was shown to produce an even sharper decrease in pAKT levels across most cell lines: phosphorylation decreased the least in G12S/G12V (61-74%) and the most in G12A/G12D/G12R mutant subtypes (94-99%). Overall, the levels of pAKT were reduced more extensively by afatinib (86%) than by gefitinib (57%) (P < 0.001).
Discussion
KRAS-dependent efficacy of therapeutic agents targeting proteins of the EGFR pathway has been described in several reports, and retrospective subgroup analyses have shown the poor benefit of such drugs in patients bearing KRAS mutant mCRC tumors [10] [11] [12] [13] [14] [15] [16] . In addition, many reports agree that some KRAS mutant variants might still rely on growth stimulation originating from members of the HER family or may be less resistance activating, making them equally or even more sensitive to treatment than wild-type cells [22, 45] .
Our model of investigation is based on isogenic cell lines showing microsatellite instability. Although this setting of cells bearing heterozygous knock-in mutations is highly artificial, it allowed us to consider the impact of KRAS mutations in an isolated manner, with a single base exchange being the only distinctive feature causing disparities in therapeutic outcome and little interference to be expected from other sources. The consequences of these mutations might be far more complex in vivo, most probably involving several different mechanisms of action that could not be explored in this setting. The scope of our investigation and our findings is further limited by the fact that SW48 colorectal cancer cells do not seem to form metastatic lesions in vivo [46] . It is also important to mention that effects that are specific to the cell line that we used may have possibly influenced our results.
Apart from KRAS wild-type cells, we selected the seven most common mutations and aimed to compare the various effects of afatinib and gefitinib on cell viability, the cell cycle, and levels of regulatory proteins. Although colorimetric cell viability assays provided somewhat coherent information on the degree of sensitivity to afatinib/gefitinib in the examined KRAS wild-type/ mutant cell lines (similar reactions to either treatment), cell cycle analysis and differences between protein levels among KRAS mutant subtypes seemed less conclusive. Certain cell lines that were relatively irresponsive to treatment in cell viability assays (e.g. G12C) and expected to show a comparable behavior in cell cycle analysis turned out to be rather sensitive to the induction of apoptosis and the inhibition of proliferation by both afatinib and gefitinib. In general, we found most cell lines to be more susceptible to the induction of apoptosis than to the inhibition of proliferation.
Afatinib and gefitinib belong to the same class of antineoplastic drugs, and yet our findings suggest that afatinib, acting as an irreversible ErbB family blocker, has a stronger inhibitory effect on EGFR and HER-2 phosphorylation than gefitinib in most of the cell lines examined. As shown previously for cetuximab [47] , activation of HER-2 might be a mechanism of resistance possibly attenuating the therapeutic effect of EGFRinhibiting agents. Afatinib may appear to be more effective because of its mechanism of blocking multiple receptor subtypes of the HER family, thus also having a greater inhibitory influence on those receptors that might act as compensatory structures in those cells that are less responsive to gefitinib [48] .
Both ERK and AKT are intermediate members of the EGFR signaling cascade and directly/implicitly subordinate to changes in KRAS activation [49] . ERK phosphorylation has been shown to be largely reliant on EGF stimulation, and intrinsic levels of pERK before/ after such stimulation were observed to depend on the mutational status of KRAS [50] . It has also been argued that in KRAS mutant colorectal cancers, KRAS acts as a principal regulator of signaling along the MEK/ERK pathway, but not along the PI3K/AKT pathway (as the latter is considered to require stimulation by receptor tyrosine kinases) [51] . This implies that TKIs would only serve to inhibit AKT in this setting, and that additional agents targeting MEK (or, in fact, other regulatory proteins along the same pathway) would be needed for sufficient therapeutic success. In this investigation, however, KRAS wild-type/mutant cells were found to be highly susceptible to the inhibitory effect of afatinib and gefitinib on both ERK and AKT, indicating that even in KRAS mutant tumors, members of the HER family still retain regulatory control over these pathways.
Although afatinib was generally shown to silence receptor activation more effectively, several KRAS mutant subtypes that were shown to be fairly insensitive to gefitinib (G12D/G12S/G12C) also proved to be relatively irresponsive to treatment with afatinib, suggesting that some cell lines have such little dependency on HER signaling that even combined inhibition of more than one type of receptor only influences cell survival to a marginal extent. Some of these KRAS mutant subtypes are frequently found in clinical samples and appear to be associated with poor outcome when treated with cetuximab-based regimens (esp. G12C); yet, it remains difficult to determine whether these mutations lead to significant resistance against TKIs in vivo [16, 44, 52] . Consistent with clinical observations [21] , we further found that SW48 G13D mutant cells are not only comparatively sensitive to treatment with TKIs (IC 50 values are lower than those evaluated for KRAS wild-type cells), but that afatinib and gefitinib strongly induce apoptosis and inhibit proliferation in this particular KRAS variant as well.
We conclude that the therapeutic impact of both afatinib and gefitinib seems to depend on the KRAS mutation status of tumor cells, with some mutant subtypes responding better (G13D) and others responding worse (G12C/G12S/G12D) to these drugs than wild-type cells. This investigation further showed afatinib to possibly be more potent than gefitinib in certain respects; its efficacy might be a consequence of its strong influence on both EGFR and HER-2. Further preclinical and clinical research on the use of TKIs in solid tumors is warranted, and subgroup analyses of clinical trials involving the use of TKIs on patients carrying KRAS wild-type/mutant tumors will hopefully provide greater insight into the exact behavior of these therapeutic agents.
